FIELD: medicine; pharmacology.
SUBSTANCE: invention concerns new agent providing protection of blood cells from cytostatic action and ionising radiation during oncologic therapy. Agent is characterised by the fact that it includes polyhaemoglobin modified with glutamine acid. Besides, invention refers to pharmacological combination including polyhaemoglobin modified with glutamine acid and cytostatic. However combination components are intended to be introduced separately or one by one. Ratio of polyhaemoglobin modified with glutamine acid and cytostatic is within 1:3 to 1:50.
EFFECT: reduced negative effect of cytostatic to hematopoietic system and improved haematopoiesis characteristics.
6 cl, 2 tbl, 3 dwg
Title | Year | Author | Number |
---|---|---|---|
USE OF POLYMERIZED HEMOGLOBIN FOR INCREASING EFFICIENCY OF MALIGNANT TUMOR CHEMOTHERAPY | 2021 |
|
RU2789607C1 |
HEMOSTIMULANT AND PHARMACEUTICAL COMPOSITION AND METHOD FOR HEMOPOIESIS STIMULATION | 2011 |
|
RU2482869C1 |
METHOD OF TREATING ONCOLOGICAL DISEASES IN EXPERIMENT | 2007 |
|
RU2396967C2 |
HEMATOPOIETIC PRECURSOR CELL DIFFERENTIATION INHIBITOR | 2006 |
|
RU2317074C1 |
BIS(2-ETHYLHEXANOATO)BIS(TRIETHYLENETETRAMINE)COBALT (II) HAVING PROPERTIES OF STIMULATOR OF HEMOPOIESIS | 1994 |
|
RU2078767C1 |
METHOD FOR STIMULATING MYELOGENESIS | 2010 |
|
RU2442589C1 |
TETRAKIS-(L-HISTIDINATO)-μ-PEROXYDICOBALT)III HEPTAHYDRATE HAVING ANTIANEMIC, RADIOPROTECTIVE AND ANTIARRHYTHMIC ACTIVITIES | 1999 |
|
RU2151773C1 |
TREATMENT METHOD FOR HEMATOPOIETIC ERYTHROID LINEAGE DEPRESSION IN CYTOSTATIC MYELOSUPRESSION | 2008 |
|
RU2364398C1 |
MEDICATION POSSESSING IMMUNOSTIMULATING AND HEMOSTIMULATING ACTION | 2009 |
|
RU2414223C1 |
PHARMACOLOGICAL COMPOSITION BASED ON WATER-SOLUBLE POLYMETAL COMPLEXES OF POLYGALACTURONIC ACID, STIMULATING HEMATOPOIESIS PROCESS | 2019 |
|
RU2704033C1 |
Authors
Dates
2008-07-10—Published
2007-03-22—Filed